Actuate Therapeutics, Inc. has taken a significant step towards its initial public offering (IPO) by filing an amendment to its S-1 registration statement with the Securities and Exchange Commission (SEC) on October 14, 2026. This amendment is crucial as it reflects the company’s ongoing efforts to raise capital and expand its operations in the competitive pharmaceutical preparations sector.
The filing comes as Actuate Therapeutics aims to sell 65 million shares of its common stock at an assumed public offering price of $0.6437 per share. This price reflects the last reported sale price of the company’s stock on the Nasdaq Global Market as of October 12, 2026. However, the actual offering price will be determined in collaboration with underwriters at the time of pricing, which may vary from this assumed price.
Background
Actuate Therapeutics, Inc., incorporated in Delaware, operates in the pharmaceutical preparations industry, classified under SIC code 2834. The company is listed on the Nasdaq under the ticker symbol ACTU. As a smaller reporting company and an emerging growth entity, Actuate Therapeutics is navigating the complexities of the public markets with a focus on innovative therapeutic solutions.
What the Filing Says
The SEC filing indicates that Actuate Therapeutics is committed to moving forward with its IPO plans. The company stated, "The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended." This statement highlights the procedural steps the company is undertaking to ensure compliance with regulatory requirements.
Impact
This amendment may affect various stakeholders, including potential investors, underwriters, and competitors in the pharmaceutical preparations sector. The filing indicates that Actuate Therapeutics is positioning itself to attract investment, which could enhance its capabilities and market presence. As the company prepares for its public offering, it will likely face competition from established firms in the industry, which may influence its market strategy and growth trajectory.
What's Next
The filing does not specify what happens next, but it is expected that Actuate Therapeutics will continue to work closely with its underwriters to finalize the offering details. Investors and market watchers will be keenly observing the next steps as the company approaches its IPO.